ufsphere.blogg.se

Secondary outcomes were different types of strokes, cardiovascular events, and adverse events. Primary outcomes were all-cause mortality and all strokes. We used GRADE to rate the overall certainty of evidence. We performed pairwise meta-analyses and trial sequential analyses (TSA) to compare statins versus placebo/no statin, and network meta-analyses using frequentist random-effects models to compare statins through indirect evidence. Two authors extracted data and appraised risks of bias. We searched for randomized controlled trials (RCTs) assessing statins in patients with ischemic stroke or transient ischemic attack (TIA) in MEDLINE, EMBASE, and CENTRAL up to July 2017. We aimed to summarize the evidence for the use of statins in secondary prevention for patients with ischemic stroke by comparing benefits and harms of various statins. Determining which statin to use remains controversial. Statins may prevent recurrent ischemic events after ischemic stroke.